Several other research analysts have also recently weighed in on the stock. Echelon Wealth Partners reaffirmed a hold rating on shares of Liminal BioSciences in a report on Tuesday, August 11th. ValuEngine raised shares of Liminal BioSciences from a hold rating to a buy rating in a report on Monday, August 17th.
Shares of LMNL stock opened at $12.55 on Tuesday. The firm’s fifty day simple moving average is $14.28. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.61 and a quick ratio of 1.33. Liminal BioSciences has a 1 year low of $5.25 and a 1 year high of $31.45. The company has a market cap of $296.53 million, a PE ratio of -3.97 and a beta of 2.23.
An institutional investor recently bought a new position in Liminal BioSciences stock. Atom Investors LP bought a new position in Liminal BioSciences (NASDAQ:LMNL) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 24,547 shares of the company’s stock, valued at approximately $265,000. Atom Investors LP owned approximately 0.10% of Liminal BioSciences as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 14.29% of the company’s stock.
Liminal BioSciences Company Profile
Liminal BioSciences Inc operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs. It operates through three segments: Small Molecule Therapeutics, Plasma Derived Therapeutics, and Bioseparations. The Small Molecule Therapeutics segment's lead product candidate is PBI-4050, which targets unmet medical needs, such as the treatment of idiopathic pulmonary fibrosis, Alström syndrome, and other fibrotic indications.
Read More: Economic Reports
Receive News & Ratings for Liminal BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminal BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.